Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 15, 2017 (9 years ago)

Ketorolac Tromethamine Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Crystallization: Particulate matter (Ketorolac Calcium Salt) was observed from several lots of retained samples.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Ketorolac Tromethamine Injection, USP 30 mg/mL, packaged in 1 mL single-dose vials, Rx only, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, CA 91730, NDC 0548-9021-00

Affected NDC 0548-9021-00

Compare with the code on your package — it is the most precise check available.

Drug: Ketorolac

Recalling firm
Amphastar Pharmaceuticals, Inc.
NDC code
0548-9021-00
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1124-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ketorolac recalls

See all

Other failed specification recalls from 2017

All failed specification recalls
Class II · Moderate risk

Valsartan Tablets

Failed Tablet/Capsule Specifications: confirmed customer complaint of thicker and heavier tablets in bottle.

Terminated Failed specification Prinston Pharmaceutical Inc NDC 43547-369-09 D-0209-2018
Class II · Moderate risk

Vertra Elemental Resistance

CGMP Deviations: products manufactured in a manner that may impact product quality that includes but is not limited to failed viscosity.

Terminated Failed specification Eai-Jr286 INC D-0100-2018
Class II · Moderate risk

Clozapine Tablets USP

Failed Tablet/Capsule Specifications; potential presence of broken tablets.

Terminated Failed specification Teva Pharmaceuticals USA NDC 00093-7772-05 D-0096-2018